ARS Pharmaceuticals (SPRY) said Wednesday that the European Patent Office has upheld all claims in one of its key patents related to its nasal epinephrine spray, covering formulations that include ingredients like Intravail.
The company said the patent is valid in over 30 European countries and protects the product through at least 2039.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments